En
menu
Site language
Ru En
Социальные сети

bitcoinist.com Here’s An Estimate Of How Much Strategy Would Make On Its Bitcoin Holdings If Price Rises 30% Each Year

Strategy, the world’s first and largest Bitcoin Treasury led by its founder Michael Saylor, recently resumed its weekly BTC buying spree after pausing purchases ahead of its earnings call on May 5. With the company now in buying mode, Saylor predicts Bitcoin’s price will rise 30% annually over the next 20 years. If that happens, […]

4 bitcoinist.com
скрыть

bitcoinmagazine.com The Trump Family Trust Bought Bitcoin-Linked Stocks in First Quarter: Filing

Bitcoin Magazine The Trump Family Trust Bought Bitcoin-Linked Stocks in First Quarter: Filing The Trump family trust disclosures show purchases of Coinbase, MARA and Strategy shares in Q1 2026 as the administration advances a more crypto-friendly policy agenda. This post The Trump Family Trust Bought Bitcoin-Linked Stocks in First Quarter: Filing first appeared on Bitcoin Magazine and is written by Micah Zimmerman.

10 bitcoinmagazine.com
скрыть

news.bitcoin.com ZachXBT Says 95% of LAB Token Is Insider-Controlled as Investigation Exposes Multi-Front Retail Rug

Onchain investigator ZachXBT has published a sweeping investigation into LAB, an AI trading terminal project with a $6 billion fully diluted valuation, alleging insiders control more than 95% of the token supply while running at least four simultaneous mechanisms to extract value from retail participants. A $6 Billion Project Built on Hidden Supply LAB launched […]

13 news.bitcoin.com
скрыть

forklog.media Claude Mythos Aids ‘White Hat’ Hackers in Breaching macOS

Cybersecurity researchers from Calif, utilizing the much-discussed AI model Claude Mythos, managed to bypass Apple's Memory Integrity Enforcement (MIE) protection mechanism in macOS. In April, the company discovered two vulnerabilities in macOS and linked them into an attack chain. This allowed a regular local user to gain root access—the highest privileges in the system. The breach was tested on an actual device with an M5 chip, where MIE protection was enabled. Experts have informed Apple of the issue and plan to publish technical details once it is resolved. In their view, Mythos could not have executed the attack alone without human assistance. It can replicate already described methods but not invent new ones. Apple's Security Errors related to improper memory operation remain the most common type of vulnerabilities almost everywhere, including iOS and macOS. In cybersecurity, there is a simple principle: if a problem cannot be completely prevented, one must accept the risk and attempt to mitigate it. One option is to make the attack much more complex and costly for the attacker. Such protective measures are not cheap. Calif emphasized that Apple acts wisely and controls the entire system—from hardware to software. Therefore, the company has integrated many protective mechanisms directly into the chips, making them very difficult to bypass. Many security experts consider Apple devices the most secure mass-market platform for regular users. The latest example is MIE. This is Apple's memory protection system, which operates using the chip's hardware capabilities. It was introduced as one of the main security features in Apple M5 and A19. It is specifically designed to stop attacks based on memory operation errors. Apple developed the system over five years. MIE disrupts all publicly known attack chains against modern versions of iOS, including the recently leaked Coruna and Darksword toolsets. Calif explored how AI can assist in creating attacks that still work even with such memory protection. The path to breaching macOS was discovered accidentally. Bruce Dang found the errors on April 25. Josh Main created the necessary tools, and by May 1, a working version was ready. “This experiment shows what might await us next. Apple developed MIE in a world where Mythos Preview did not yet exist. Now we will see how the world's best protection technology withstands the first major wave of vulnerabilities found with AI,” the experts concluded. Back in April, Anthropic declined to release Mythos publicly due to high security risks.

29 forklog.media
скрыть

blockonomi.com Stablecoin Inflows on Nexo Hit 2026 High as Investors Split Strategies

TLDR: Stablecoin inflows on Nexo averaged over $4 million monthly during April and May 2026 activity. CryptoQuant linked inflows to yield demand and traders seeking exposure below Bitcoin’s $75K level. Total stablecoin market capitalization climbed above $321 billion during the latest liquidity surge. Crypto investors split between cautious yield strategies and capital prepared for market [...] The post Stablecoin Inflows on Nexo Hit 2026 High as Investors Split Strategies appeared first on Blockonomi.

36 blockonomi.com
скрыть

btcmanager.com With $87m net profit in 2025, Gurhan Kiziloz’s Nexus International posts its strongest year yet

Nexus International reports record financial results under founder Gurhan Kiziloz’s independent ownership. In an industry where scale is typically equated with institutional backing, Gurhan Kiziloz has built a counter-example. Nexus International, the gaming group he founded and wholly owns, has…

37 btcmanager.com
скрыть

bitcoinist.com Bitcoin Treasury Firm Strive Pushes SATA As Rival To Strategy’s STRC

Strive is turning its SATA preferred stock into a daily-dividend Bitcoin treasury product, positioning the security as a higher-yield, faster-paying alternative to Strategy’s STRC just as Michael Saylor’s preferred-stock vehicle posted record trading activity. The company said SATA will begin paying cash dividends every business day from June 16, 2026, while maintaining a 13.00% annualized […]

44 bitcoinist.com
скрыть

blockonomi.com CME and NYSE Push US Scrutiny on Hyperliquid as HYPE Holds Gains

TLDR: Hyperliquid briefly pushed near $44 after reports tied CME and NYSE to regulatory pressure Critics questioned Hyperliquid’s HLP vault structure and trader loss-linked protocol revenue CoinGecko data showed $HYPE trading near $43.61 with nearly $887 million daily volume ZachXBT raised questions after NYSE-linked criticism targeted Hyperliquid instead of Polymarket Hyperliquid entered fresh regulatory discussions [...] The post CME and NYSE Push US Scrutiny on Hyperliquid as HYPE Holds Gains appeared first on Blockonomi.

47 blockonomi.com
скрыть

bitcoinmagazine.com DMND and RootstockLabs Partner To Bring Stratum V2 To Merge-mining

Bitcoin Magazine DMND and RootstockLabs Partner To Bring Stratum V2 To Merge-mining DMND and RootstockLabs partner to enable miners to select their own sidechain blocks using Stratum V2. This post DMND and RootstockLabs Partner To Bring Stratum V2 To Merge-mining first appeared on Bitcoin Magazine and is written by Shinobi.

56 bitcoinmagazine.com
скрыть

news.bitcoin.com BiggerZ.com Strengthens its International Presence With Crypto iGaming and Sportsbook Platform

This sponsored press release was provided by BiggerZ and was not written by Bitcoin.com News. Bitcoin.com News does not necessarily endorse the statements made within this announcement. PRESS RELEASE. BiggerZ.com continues to expand its global footprint as a crypto casino and sportsbook platform offering multi-currency payments, online casino games, and international sports betting markets. The […]

59 news.bitcoin.com
скрыть

blockmanity.com Crypto Market Dip Today: Why It’s Down 0.32% and Key Supports Holding Firm

Crypto Market Dip Today: Why It’s Down 0.32% and Key Supports Holding Firm The crypto market is seeing a small drop today. The total market cap sits at $2.66 trillion, down just 0.32% or about $8.52 billion from yesterday. This […] The post Crypto Market Dip Today: Why It’s Down 0.32% and Key Supports Holding Firm appeared first on Blockmanity.

64 blockmanity.com
скрыть

forklog.media Bitcoin Tests Breakeven Level for Short-Term Whales

The price of the leading cryptocurrency has returned for the third time since October to the average purchase price of short-term whales, around $79,000-$80,000. This was reported by on-chain analyst known as MorenoDV. Short-Term Whales Decide the Next Move“If BTC can stabilize above this cohort’s cost basis, unrealized stress disappears & these whales may transition from defensive sellers into passive holders again, removing significant sell-side pressure from the market.” – By @MorenoDV_ pic.twitter.com/ipxXym3Hxr— CryptoQuant.com (@cryptoquant_com) May 15, 2026 A group of large investors, who previously recorded unrealized losses, has reached the breakeven point. According to the expert's observations, short-term whales tend to make emotional decisions and react more sharply to market changes than long-term holders. Their priorities are current profit indicators and risk management, rather than a deep belief in the asset. The previous two similar tests in October 2025 and January 2026 ended in capitulation. At that time, the price briefly rose above the whales' entry level, but after losing momentum, investors began to actively sell coins, locking in losses. The situation has reached a critical point. If Bitcoin stabilizes above $80,000, large holders will shift from sellers to passive holders, easing market pressure. Otherwise, a new wave of sharp sales is expected. At the time of writing, digital gold is trading at $80,470, up 1.3% over the past day. Hourly chart of BTC/USDT on Binance. Source: TradingView. Earlier in May, analysts at JPMorgan predicted further underperformance of Ethereum compared to Bitcoin.

65 forklog.media
скрыть

news.bitcoin.com Multicoin’s DeFi Disaster: Firm Spotted Dumping AAVE After Brutal 55% Drawdown

Onchain data shows Multicoin Capital is now more than $40 million underwater on a large AAVE position built through Galaxy Digital’s over-the-counter (OTC) desk. The firm now appears to be selling. A $73.7 Million Bet Gone Wrong Between October 13 and November 25, 2025, Multicoin Capital received 338,005 AAVE tokens from a Galaxy Digital OTC […]

70 news.bitcoin.com
скрыть

blockonomi.com Kooc Media Expands PR Distribution Network With Dedicated AI Startup Services

Kooc Media, a specialist PR distribution agency covering the crypto, fintech, iGaming and technology sectors, has officially launched a dedicated PR service for AI startups, AI tool developers and companies building artificial intelligence products. The new offering is available now through the agency’s AI PR page. The service brings the same guaranteed media placement model [...] The post Kooc Media Expands PR Distribution Network With Dedicated AI Startup Services appeared first on Blockonomi.

74 blockonomi.com
скрыть

bitcoinmagazine.com Strategy (MSTR) Files to Repurchase $1.5B in 2029 Convertible Notes as STRC Hits Record $1.53B Daily Volume

Bitcoin Magazine Strategy (MSTR) Files to Repurchase $1.5B in 2029 Convertible Notes as STRC Hits Record $1.53B Daily Volume Strategy said Friday it plans to repurchase $1.5 billion in 2029 convertible notes as investor demand for its STRC preferred stock continues to surge. This post Strategy (MSTR) Files to Repurchase $1.5B in 2029 Convertible Notes as STRC Hits Record $1.53B Daily Volume first appeared on Bitcoin Magazine and is written by Micah Zimmerman.

88 bitcoinmagazine.com
скрыть

blockonomi.com Ethereum Exchange Inflows on Binance Signal Distribution Phase as TD Sequential Flashes Sell Alert

TLDR: Binance ETH reserves surged from 3.36M to 3.84M between May 5 and May 10, signaling heavy exchange inflows. ETH has ranged between $2,200 and $2,400 for nearly a month, with rallies failing to sustain upside momentum. On-chain Exchange Inflow Mean data confirms large ETH transfers to Binance, pointing to an active distribution phase. A [...] The post Ethereum Exchange Inflows on Binance Signal Distribution Phase as TD Sequential Flashes Sell Alert appeared first on Blockonomi.

89 blockonomi.com
скрыть

bitcoinist.com Crypto Analytics Firm Dune Axes 25% Of Employees Amid Strategic Overhaul

Dune’s CEO announced Thursday that the crypto data company is cutting a quarter of its staff as part of a broader push to build out data tools for institutional investors — a segment the company sees as a major growth opportunity as more traditional financial assets move onto blockchain networks. Related Reading: Bitcoin Slump Forces […]

91 bitcoinist.com
скрыть

forklog.media The sensible person’s AI

Hype, speculation and alarming forecasts aside, few specialists doubt that artificial intelligence will change the world. Who gains and at what cost remains unsettled. History shows that breakthroughs bring crises as well as opportunities, forcing societies to rebalance. One field, though, has long shown almost unambiguous gains from technological progress: medicine. ForkLog examines how, even today, AI accelerates the creation of new drugs, optimises lab workflows, sharpens diagnosis and reshapes approaches to treatment. Drug discovery Most medicines act by binding to protein receptors—molecular structures that regulate cellular function and feature in almost all bodily processes. AI systems can analyse receptor structures and predict which compounds will bind most effectively with minimal side-effects. That is why tasks that once took years of lab work are increasingly being solved in months. According to estimates by the World Health Organization (WHO), most new pharmaceuticals in the coming years will in some way be developed with AI. AlphaFold and Isomorphic Labs In 2024 the Nobel Prize in Chemistry went to David Baker, Demis Hassabis and John Jumper. The latter two work at Google DeepMind and were recognised for protein-structure prediction methods, including AlphaFold, built on machine learning. In 2018 AlphaFold took first place in the protein-structure “contest” Critical Assessment of Structure Prediction (CASP), excelling in the hardest categories. Two years later, at the next CASP, a new version—AlphaFold 2—won. In 2021 Google DeepMind released the AlphaFold2 code and a database of predicted protein structures. Around the same time Hassabis founded Isomorphic Labs, an Alphabet subsidiary focused on AI for drug discovery. In 2024 Isomorphic Labs struck partnerships with Eli Lilly and Novartis. The deals envisaged funding of up to $1.7bn and $1.2bn, respectively, for the company’s AI research. In 2026 Isomorphic Labs also announced a partnership with Johnson & Johnson. In February 2026 Isomorphic Labs unveiled a universal drug-design environment, Drug Design Engine (IsoDDE), built on AlphaFold technologies. The firm is working on oncology and immunology. Despite AI-driven acceleration, projects remain at the preclinical stage. The company expects to begin first-in-human trials in the coming years. Exscientia and Recursion Pharmaceuticals Founded in 2012, Exscientia was among the first companies to apply machine learning systematically to drug design. In 2020 the drug DSP-1181 for therapy in OCD became the first AI-designed product to reach clinical trials. The project was conducted with Japan’s Sumitomo Dainippon Pharma, which handled synthesis and lab tests, guided by Exscientia’s theoretical results. By 2023 the company had eight candidate molecules ready, developed “substantially faster” than the industry average. In 2024 Recursion Pharmaceuticals acquired Exscientia in a $688m deal. Some research programmes were shut. By then several drugs had reached phase II—testing efficacy and side-effects in a cohort of 100–300 patients. The tie-up with Recursion Pharmaceuticals combined Exscientia’s AI systems with an automated lab-testing complex. Recursion also built its own AI supercomputer, BioHive-2, on NVIDIA H100s to train specialised models. The company also contributed to the open, generative model Boltz-2 for predicting proteins’ three-dimensional structures.By 2025 Recursion Pharmaceuticals focused on four oncology programmes and two related to rare diseases. Several drugs sit between phase I and II: REC-4881 for familial adenomatous polyposis, a disease that increases the risk of colorectal cancer; REC-617 for ovarian malignancies; REC-1245 for lymphoma and other cancers. REC-3565, designed for treating chronic lymphocytic leukaemia, is in phase I trials. Insilico Medicine Founded in 2014, Insilico Medicine is another significant player in AI-driven drug development. In 2017 Insilico Medicine was named to Nvidia’s top five for social impact. The company uses AI across the development cycle: PandaOmics identifies biological “targets”—molecules to be “switched off” or modulated by therapy; Chemistry42 provides generative design of candidate compounds; InClinico optimises clinical-trial forecasting. One early AI milestone for Insilico Medicine is Rentosertib (ISM001-055), linked to fibrosis treatment. Development took 18 months from an AI-identified target to a candidate molecule. As of 2025, Rentosertib is in phase II trials. Also in 2024, the AI-designed immunomodulatory ISM3312 for COVID-19 and other viral infections completed phase I. ISM3091, related to cancer therapy, was admitted to patient testing. Diagnostics and research Specialists estimate that about 90% of all medical information is represented by images such as X-rays and scans. These data are critical to diagnosis, but labour-intensive and tricky to read. Machine-learning methods, especially convolutional neural networks, suit complex visual pattern recognition. Much like human vision, such systems can pick out contrasts, edges, shapes and textures. This allows tumours, bleeds and other anomalies to be found with high confidence. Model training benefits from high-quality datasets—large archives of documented images with expert annotations. In 2024 researchers at Harvard Medical School presented an AI model, Chief, that can detect several cancers. According to the team, it correctly spotted signs of disease on digital images in 94% of cases. In 2025 America’s Food and Drug Administration (FDA) granted “breakthrough device” status to Damo Panda, a model from Alibaba’s Damo Academy. According to its developers, the system can flag pancreatic cancer on scans before symptoms appear—vital for this particularly insidious disease. In 2026 a significant breakthrough in AI diagnostics was REDMOD, developed by the Mayo Clinic, a US non-profit. The model, also aimed at detecting pancreatic cancer, outperformed specialists at early-stage diagnosis. The researchers said it found pathological changes on scans a median 475 days before diagnosis. Google’s initiatives Google is a key provider of AI for medical diagnostics and research. The company offers MedGemma, an open family of models for medical text, image and audio analysis MedGemma based on Gemma 3. Through Health AI Developer Foundations, developers can access open weights and tools. Google collaborates with clinics and research organisations, focusing on foundational technologies. In 2019 the company introduced a model to detect and forecast lung cancer. It matched or beat a panel of six certified radiologists. In 2020, with Northwestern Medicine, researchers demonstrated a system for mammogram analysis that could detect cancer at a specialist’s level. In 2024 Google Cloud and Germany’s Bayer announced a platform for X-ray screening. It reviews imaging histories and medical records to suggest possible pathologies. NVIDIA and GE HealthCare’s autonomous imaging Tech giant Nvidia and American medtech firm GE HealthCare, a maker of X-ray equipment, are developing an AI system for autonomous image acquisition. Unlike models that analyse images after the fact, this system aims to reduce clinicians’ routine workload and standardise diagnostics. The first phase will focus on X-rays and ultrasound. GE HealthCare also plans to use NVIDIA Isaac for Healthcare, a platform for building autonomous medical systems, including surgical robots. PathAI’s diagnostic platform Founded in 2016, PathAI has built a “digital pathology platform”, AISight Dx, for primary diagnosis in clinical settings. The system provides a workspace for medical images with the option to plug in third-party algorithms. The platform supports a set of CE‑IVD-certified, AI-based tools—specifically, oncology “plug-ins”: DeepDx Prostate automatically highlights tissues and flags potentially important regions; Histotype Px Colorectal predicts disease course from images, gauges the value of chemotherapy and offers therapeutic suggestions; Visiopharm detects and counts biomarkers for various cancers. The platform also includes native functions for automated image analysis, diagnostic assistance and report drafting, but these are “for research use only” and not permitted for clinical application. AISight Dx also offers built-in assistive AI tools: ArtifactDetect, to find scanning artefacts and other image errors; Case Priority, to prioritise clinical cases based on tissue analysis; AIM-Tumor Cellularity, to assess tumour cellularity. In 2022 the platform received US FDA clearance via 510(k) and Europe’s CE mark, attesting to safety for consumers and the environment. In 2025 PathAI announced a partnership with the Moffitt Cancer Center in Florida, USA, to deploy AISight Dx in diagnostics. In 2026 the company signed a similar agreement with University Hospital Zurich. In May 2026 Swiss drugmaker Roche said it would acquire PathAI in a deal worth over $750m. Pitfalls and limits As elsewhere, AI in medicine exposes old problems and creates new ones. AI assistants, especially those based on LLMs, are prone to hallucinations. In a research paper on Med-Gemini by Google, an error surfaced: the model “invented” a non-existent brain region called the basilar ganglia. The hallucination blended two real anatomical terms: the basal ganglia and the basilar artery. The developers blamed a typo, but several specialists called the incident a worrying example of the risks of deploying AI assistants in medicine. Researchers at Stanford University found that some models could convincingly diagnose from medical images without access to the images themselves. One system scored highly “blind” on a radiology test. GPT-5, Gemini 3 Pro and Claude Opus 4.5 “confidently described visual details” on non-existent images. According to a June study, in a medical context 7.1% of GPT-4’s replies to patient questions were incorrect and could have caused significant harm. One in 156 posed a life-threatening risk. As of 2025, tools that auto-generate documentation from doctor–patient conversations introduced errors into 70% of clinical notes—adding false facts, omitting points and muddling concepts. Beyond inventing organs, LLMs are notoriously opaque, making it hard for humans to interrogate their reasoning. Poorly representative datasets can bake in biases and spurious correlations. Meanwhile, familiar issues for AI assistants—user over-reliance and data privacy—are only sharper in healthcare. WHO experts class medical AI as high risk. Under Europe’s AI Act, from August 2026 such systems must meet special requirements for risk management, reporting and human oversight. Despite the challenges and risks, WHO sees promise in medical AI—given proper rules and government oversight. The US FDA is also optimistic about AI’s prospects, while acknowledging that current regulation is dated. In the US these systems are formally classed as Software as a Medical Device. In 2025 the FDA published guidance on product lifecycle, risk management and marketing.

92 forklog.media
скрыть

blockonomi.com UK FCA Investigates Mastercard, Visa, and PayPal Over Anti-Competitive Digital Wallet Practices

TLDR: The FCA is probing Mastercard, Visa, and PayPal under Chapter I of the Competition Act 1998 for restricted competition. Mastercard and Visa face the more serious Chapter II charges, which target the abuse of a dominant market position. The investigation was triggered by PayPal Holdings Inc’s public financial disclosures, not a formal external complaint. [...] The post UK FCA Investigates Mastercard, Visa, and PayPal Over Anti-Competitive Digital Wallet Practices appeared first on Blockonomi.

95 blockonomi.com
скрыть

forklog.media SharpLink Criticizes Strategy’s Approach to Crypto Asset Management

Ethereum companies are moving away from the capital management model popularized by Strategy's founder, Michael Saylor. This was stated by SharpLink Gaming's CEO, Joseph Shalom, in an interview with The Block. According to him, firms within the Ethereum ecosystem are focusing on income from staking and simplifying balances, in contrast to Saylor's "financial engineering," which often employs leverage for aggressive Bitcoin investments. Shalom considers Ethereum a more efficient reserve asset: token holders receive passive income directly. SharpLink has accumulated 868,699 ETH, valued at approximately $1.96 billion, ranking second in the market after BitMine, which holds over 5.1 million ETH. The head of SharpLink noted that many industry players suffered due to the issuance of convertible bonds and preferred securities in the early stages. SharpLink focused on raising equity capital and staking, which allowed it to maintain resilience despite a 91% drop in shares from 2025 highs. Shalom also highlighted the trend towards tokenization of assets and the growing use of stablecoins. He mentioned plans by NYSE and Nasdaq to transition to 24/7 trading and developments by DTCC in the area of RWA-backed securities. According to the executive, Ethereum's correlation with Bitcoin and the tech sector will weaken in the future. Growth drivers will include the development of DeFi, tokenization of real-world assets, and AI integration into blockchain. Bit Digital's Revenue Decline The mining company Bit Digital released its financial report for the first quarter. Total revenue amounted to $27.9 million, a 13.6% decrease from the previous period. Key figures: Net loss: $146.7 million (compared to $185.3 million in the fourth quarter of 2025), driven by the revaluation of digital assets; Cash: $79.5 million; Digital asset volume: $295 million; Ethereum holdings: 155,444 ETH valued at approximately $327 million. Bitcoin mining revenue fell by 32.9% to $3.7 million. The company confirmed its strategy to reduce reliance on mining the first cryptocurrency in favor of the Ethereum ecosystem and AI infrastructure. Ethereum staking revenue dropped to $2.3 million amid a decline in the asset's price. To enhance balance flexibility, the company transferred 70,000 ETH to liquid staking protocols. Cloud services generated $16.8 million. The colocation segment (equipment placement) showed a 23.9% increase, generating $4.8 million in revenue. Bit Digital holds a controlling stake in AI infrastructure operator WhiteFiber. The company's head, Sam Tabar, stated that the future of the financial system is built at the intersection of AI and Ethereum. "We provide computational infrastructure through WhiteFiber and settlement paths through our Ethereum staking platform. These are parts of a unified platform," he emphasized. Back in May, BitMine's chairman, Tom Lee, announced that the company had nearly reached its Ethereum accumulation goal and plans to slow down purchases.

97 forklog.media
скрыть

blockonomi.com David Schwartz Details Tech Guarding XRP From Big Firms

TLDR Charles Hoskinson described the XRP Ledger architecture as “very elegant,” which renewed debate about decentralization. Ripple CTO Emeritus David Schwartz explained how the network prevents corporate capture while maintaining stability. Schwartz stated that large corporations can dominate networks if technical perfection becomes the only priority. The XRP Ledger encourages participation from independent validators across [...] The post David Schwartz Details Tech Guarding XRP From Big Firms appeared first on Blockonomi.

98 blockonomi.com
скрыть

cryptopotato.com How to Swap Monero (XMR) on StealthEX

The world of cryptocurrencies is evolving, but one thing remains a constant – privacy. It still is a paramount concern for many users. While Bitcoin and Ethereum offer a degree of transparency through public ledgers, it can sometimes also compromise anonymity. This is where protocols like Monero (XMR) step in. However, acquiring or swapping Monero […]

100 cryptopotato.com
скрыть